SPON2 and neoplasm: Though this study demonstrated preliminary serum reactivity of synthetic SPON2 and MSMB epitopes by ELISA, we did not perform quantitative protein-level validation using standard ELISA kits or immunoblotting, nor did we conduct immunohistochemistry (IHC) on tumor tissues.